Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07300969) titled 'A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression' on Dec. 22, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Triple (Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Draig Therapeutics Ltd
Condition:
Major Depressive Disorder (MDD)
Intervention:
Drug: DT-101
Drug: DT-101
Recruitment Status: Recruiting
Phase: Phase 2
Date of First Enrollment: December 16, 2025
Target Sample Size: 300
Countries of Recruitment:
United States
To know more, visit https://clinical...